Safety Profile

Melanotan II Side Effects: Frequency & Severity

Melanotan II has a higher side effect burden than other peptides due to its non-selective melanocortin activity.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Serious side effects

1
  • Melanoma risk

    Case reports of atypical melanomas in melanotan users. Causality not established but a serious concern.

Common side effects

7
  • Nausea

    Particularly in first doses; often severe.

  • Facial flushing

    Melanocortin-mediated.

  • Loss of appetite

    Can be substantial.

  • Skin darkening

    Expected effect; generalized and/or patchy.

  • Moles/nevi changes

    Existing moles may darken or enlarge; new moles may appear.

  • Spontaneous erections (male)

    MC4R activation; can be prolonged.

  • Yawning

    Melanocortin-related; distinctive side effect.

Uncommon side effects

2
  • Dizziness

    Transient.

  • Increased blood pressure

    Transient.

Rare side effects

1
  • Priapism

    Prolonged erection; requires medical attention.

Contraindications

  • Personal or family history of melanoma
  • Numerous or atypical nevi
  • Active malignancy
  • Pregnancy and lactation
  • Known hypersensitivity

Drug interactions

  • PDE5 inhibitors — additive erection effects; increased priapism risk
  • Alpha-blockers — unknown combined effect

Special populations

Not FDA approved. Not recommended in any special population. High safety concern profile.

Overall safety summary

Melanotan II has the highest concerning side effect profile on PeptideMark. Skin cancer concerns, priapism, and significant nausea are all substantial risks. PT-141 (bremelanotide) is a safer selective alternative for sexual function, and it is FDA approved.

Melanotan II side effects: FAQ

Can Melanotan II cause melanoma?

Case reports describe atypical melanomas in users. Causality has not been proven, but the theoretical mechanism (darkening and proliferation of pigmented lesions) is biologically plausible. Avoid if personal or family history of melanoma.